<DOC>
	<DOC>NCT01125410</DOC>
	<brief_summary>The purpose of this clinical study was to evaluate whether vaginal tablets containing 10 mg dequalinium chloride (Fluomizin) are comparable in clinical efficacy and safety to clindamycin vaginal cream (2%) in patients suffering from bacterial vaginosis.</brief_summary>
	<brief_title>Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis</brief_title>
	<detailed_description>An international, multi-center, single-blind, randomized, active-controlled study with two parallel groups in patients with bacterial vaginosis. Eligible patients were randomized to receive Fluomizin vaginal tablets for 6 days or Clindamycin vaginal cream (2%) for 7 days. Control examinations were performed 3 to 14 days and 2 to 6 weeks after the end of the therapy.</detailed_description>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis, Bacterial</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Dequalinium</mesh_term>
	<criteria>Diagnosis of bacterial vaginosis Women aged 1855 years Pregnancy or lactation Uterine bleeding (including menstruation but not including cervical contact bleeding on sampling) or vaginal bleeding of unknown origin Acute infections of the upper genital tract Clinical Symptoms of a vulvovaginal Candidiasis Use of antiinfectives (local or systemic) in the previous 14 days and/or during the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Fluomizin</keyword>
	<keyword>Dequalinium chloride</keyword>
	<keyword>Bacterial vaginosis</keyword>
	<keyword>vaginal therapy</keyword>
</DOC>